Blepharospasm as a Manifestation of Peak of Dose Dyskinesia in Parkinson Disease

Clin Neuropharmacol. 2019 Jan/Feb;42(1):14-16. doi: 10.1097/WNF.0000000000000316.

Abstract

Objectives: The aim of the study was to report 4 patients with Parkinson disease (PD) and On-period blepharospasm (BS).

Methods: We analyzed patients with PD and motor fluctuations who developed BS in several different centers in Latin America.

Results: Four patients had BS while in the ON periods.

Conclusions: Blepharospasm in the On period in patients with PD is extremely uncommon, and our series is the only one to describe such association.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / adverse effects
  • Blepharospasm / chemically induced
  • Blepharospasm / drug therapy*
  • Blepharospasm / etiology*
  • Botulinum Toxins, Type A / adverse effects
  • Botulinum Toxins, Type A / therapeutic use
  • Carbidopa / adverse effects
  • Carbidopa / therapeutic use
  • Drug Combinations
  • Dyskinesias / drug therapy
  • Dyskinesias / physiopathology
  • Humans
  • Levodopa / administration & dosage*
  • Levodopa / adverse effects*
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology*

Substances

  • Antiparkinson Agents
  • Drug Combinations
  • carbidopa, levodopa drug combination
  • Levodopa
  • Botulinum Toxins, Type A
  • onabotulinum toxin A
  • Carbidopa